---
id: 124
title: Pneumocystis jirovecii Pneumonia (PCP)
category: organisms
subcategory: fungi
tags: [PCP, Pneumocystis, TMP-SMX, pentamidine, HIV, prophylaxis]
difficulty: medium
---

## Question

How is PCP diagnosed and treated? Use the **"TMP-SMX (High-Dose) + Prednisone if PaO2 <70"** framework.

## Answer

### ***Pneumocystis jirovecii* Pneumonia (PCP):**

**Risk Factors:**
- **HIV/AIDS** (CD4 <200) - most common
- **Prolonged corticosteroids** (≥20mg prednisone × ≥4 weeks)
- **Hematologic malignancies** (especially ALL)
- **Solid organ transplant**
- **Inflammatory conditions** on immunosuppression (GPA, inflammatory myopathies)

**Clinical Presentation:**
- **Subacute onset** (days to weeks)
- **Dyspnea**, **dry cough**, **fever**
- **Hypoxemia** (often severe, ↑A-a gradient)
- **CXR:** **Bilateral ground-glass or interstitial infiltrates** (perihilar), can be normal early

### **Treatment:**

**Preferred (First-Line):**
- **TMP-SMX** (trimethoprim 15-20 mg/kg/day + sulfamethoxazole 75-100 mg/kg/day) IV or PO, divided q6-8h
  - Example: **TMP-SMX DS (160/800mg) 2 tablets PO TID** (for ~70kg patient)
- **Duration:** **21 days** (HIV), **14 days** (non-HIV)

**Adjunctive Corticosteroids:**
- **Indication:** **PaO2 <70 mmHg** OR **A-a gradient >35 mmHg** (on room air)
- **Prednisone 40mg PO BID × 5 days** → **40mg daily × 5 days** → **20mg daily × 11 days** (total 21 days)
- **Start within 72h** of antibiotics (improves survival, reduces respiratory failure)

**Alternatives (if TMP-SMX intolerant):**
- **Pentamidine 4 mg/kg IV daily** × 21 days (toxic: hypotension, hypoglycemia → hyperglycemia, pancreatitis, nephrotoxicity)
- **Clindamycin 600-900mg IV q6-8h + primaquine 30mg PO daily** × 21 days (moderate-severe)
- **Atovaquone 750mg PO BID** × 21 days (mild-moderate only, NOT for severe)

### **Diagnosis:**

| Test | Specimen | Sensitivity | Notes |
|------|----------|-------------|-------|
| **Immunofluorescence (DFA)** OR **PCR** | **BAL** | **>95%** | **Gold standard** |
| **Silver stain** (Gomori methenamine silver, GMS) | BAL, sputum | 90-95% (BAL) | Visualizes cysts |
| **β-D-glucan** | Serum | 90-95% | **Not specific** (positive with *Candida*, *Aspergillus*), **negative does NOT rule out** |
| **Induced sputum** | Sputum | 50-90% | Non-invasive, less sensitive than BAL |

**Imaging:**
- **CXR:** Bilateral ground-glass infiltrates (perihilar), can be normal in 10-20%
- **CT chest:** Ground-glass opacities (more sensitive than CXR)
- **Cystic changes, pneumothorax** (10-30% of HIV patients)

## Key Points

### **Prophylaxis:**

**Indications:**
- **HIV:** CD4 <200 OR CD4 <14% OR oropharyngeal candidiasis
- **Prolonged corticosteroids:** ≥20mg prednisone (or equivalent) × ≥4 weeks
- **Hematologic malignancies:** ALL, HSCT, prolonged neutropenia
- **Inflammatory diseases:** GPA (granulomatosis with polyangiitis), inflammatory myopathies on immunosuppression

**Regimens:**
- **TMP-SMX DS (160/800mg) daily** OR **3×/week** (preferred)
- **Alternatives:**
  - **Dapsone 100mg PO daily** (check G6PD first)
  - **Atovaquone 1500mg PO daily**
  - **Pentamidine 300mg inhaled monthly** (via Respigard II nebulizer)

**Stopping Prophylaxis (HIV):**
- **CD4 >200 × 3 months** on ART (can safely discontinue)

### **TMP-SMX Adverse Effects:**
- **Rash** (common, 20-50% in HIV)
- **GI upset** (nausea, vomiting)
- **Hyperkalemia** (TMP blocks ENaC, similar to amiloride)
- **Bone marrow suppression** (anemia, thrombocytopenia, leukopenia)
- **Hepatotoxicity**
- **Stevens-Johnson syndrome** (rare)

### **Pentamidine Toxicity:**
- **Hypotension** (infusion-related, give over 1-2 hours)
- **Hypoglycemia** (early, days 5-7) → **hyperglycemia/diabetes** (late, pancreatic β-cell destruction)
- **Pancreatitis**, **nephrotoxicity**
- **QT prolongation**, **torsades**

### **Clinical Pearls:**
- **TMP-SMX 15-20 mg/kg/day (TMP component) × 21 days** (HIV) or 14 days (non-HIV)
- **Prednisone if PaO2 <70** or A-a gradient >35 (start within 72h)
- **BAL with DFA/PCR** gold standard for diagnosis
- **Prophylaxis:** TMP-SMX DS daily or 3×/week (HIV: CD4 <200)
- **Atovaquone ONLY for mild-moderate** (not severe)
- **β-D-glucan positive** but NOT specific (also positive with *Candida*, *Aspergillus*)

## Sources

- [CDC/NIH/IDSA: OI Guidelines in HIV 2024]
- [ATS: PCP Treatment Guidelines 2023]

## Media

N/A
